Literature DB >> 23710708

Tenuigenin attenuates α-synuclein-induced cytotoxicity by down-regulating polo-like kinase 3.

Jin-Xia Zhou1, Hao-Bo Zhang, Yue Huang, Yi He, Yan Zheng, John P Anderson, Wei-Ping Gai, Zhi-Gang Liang, Yong Wang, Xin-Miao Ren, Qi Wang, Xiao-Li Gong, Jian Yang, Xuan Wang, Glenda Halliday, Xiao-Min Wang.   

Abstract

BACKGROUND AND AIMS: Tenuigenin (Ten) is a Chinese herbal extract with antioxidative and antiinflammatory effects on toxin-induced cell models of Parkinson's disease (PD); however, its effects on α-synuclein toxicity-based PD models remain unknown. α-synuclein hyperphosphorylation is a key event in PD pathogenesis and potential target of therapeutic interventions. We tested whether Ten alleviates α-synuclein-induced cytotoxicity via reducing kinases that phosphorylate α-synuclein.
METHODS: SH-SY5Y cells transiently transfected with wild-type or A53T mutant α-synuclein were used to evaluate the effect of Ten on the levels of α-synuclein phosphorylation-related kinases. Cells treated with 10 μM Ten for 24 h were measured for viability (proliferation and apoptosis assays) and cellular proteins harvested and fractioned. The levels of total and phosphorylated α-synuclein and five associated kinases (polo-like kinase [PLK] 1-3, casein kinase [CK] 1-2) were evaluated by Western blotting.
RESULTS: Overexpression of either wild-type or A53T mutant α-synuclein decreased cell viability and increased α-synuclein phosphorylation. Ten treatment-protected cells from this α-synuclein-induced toxicity and dramatically reduced α-synuclein phosphorylation and PLK3 (but not other kinase) levels.
CONCLUSION: In α-synuclein cell model of PD, Ten is effective in attenuating α-synuclein-induced toxicity and α-synuclein phosphorylation probably via targeting PLK3, suggesting it could be an efficient therapeutic drug to treat α-synuclein-related neurodegeneration.
© 2013 John Wiley & Sons Ltd.

Entities:  

Keywords:  Kinase; Parkinson's disease; Phosphorylation; Tenuigenin; α-synuclein

Mesh:

Substances:

Year:  2013        PMID: 23710708      PMCID: PMC6493467          DOI: 10.1111/cns.12124

Source DB:  PubMed          Journal:  CNS Neurosci Ther        ISSN: 1755-5930            Impact factor:   5.243


  5 in total

1.  Inhibition of Endoplasmic Reticulum Stress is Involved in the Neuroprotective Effect of bFGF in the 6-OHDA-Induced Parkinson's Disease Model.

Authors:  Pingtao Cai; Jingjing Ye; Jingjing Zhu; Dan Liu; Daqing Chen; Xiaojie Wei; Noah R Johnson; Zhouguang Wang; Hongyu Zhang; Guodong Cao; Jian Xiao; Junming Ye; Li Lin
Journal:  Aging Dis       Date:  2016-01-17       Impact factor: 6.745

Review 2.  Endoplasmic reticulum stress: relevance and therapeutics in central nervous system diseases.

Authors:  Hong-Yu Zhang; Zhou-guang Wang; Xiang-Hong Lu; Xiao-Xia Kong; Fen-Zan Wu; Li Lin; Xiaohua Tan; Li-Bing Ye; Jian Xiao
Journal:  Mol Neurobiol       Date:  2014-07-22       Impact factor: 5.590

3.  Fibroblast growth factor 1attenuates 6-hydroxydopamine-induced neurotoxicity: an in vitro and in vivo investigation in experimental models of parkinson's disease.

Authors:  Xiaojie Wei; Songbin He; Zhouguang Wang; Jiamin Wu; Jinjing Zhang; Yi Cheng; Jie Yang; Xinlong Xu; Zaifeng Chen; Junmin Ye; Li Chen; Li Lin; Jian Xiao
Journal:  Am J Transl Res       Date:  2014-11-22       Impact factor: 4.060

Review 4.  The role of Plk3 in oncogenesis.

Authors:  C Helmke; S Becker; K Strebhardt
Journal:  Oncogene       Date:  2015-04-27       Impact factor: 9.867

5.  Molecular Effects of L-dopa Therapy in Parkinson's Disease.

Authors:  Jolanta Dorszewska; Michal Prendecki; Margarita Lianeri; Wojciech Kozubski
Journal:  Curr Genomics       Date:  2014-02       Impact factor: 2.236

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.